Chesley Taft & Associates LLC Acquires 60,956 Shares of Pfizer Inc. $PFE

Key Points

• Chesley Taft & Associates LLC boosted its stake in Pfizer by 41.3%, purchasing 60,956 shares to own 208,557 shares valued at about $5.19 million, according to its SEC filing.
• Pfizer beat Q4 estimates with EPS of $0.66 versus $0.57 and revenue of $17.56B versus $16.93B (revenue down 1.2% YoY), yet analysts' consensus remains a "Hold" with a $28.19 price target.
• Late‑stage clinical wins — including a partnered 6‑valent Lyme vaccine showing ~75% Phase 3 efficacy and positive oncology/immunology readouts — have spurred bullish coverage and upgrades, but political pricing risks and dividend sustainability concerns pose notable downside risks.

Chesley Taft & Associates LLC boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 41.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 208,557 shares of the biopharmaceutical company's stock after purchasing an additional 60,956 shares during the period. Chesley Taft & Associates LLC's holdings in Pfizer were worth $5,193,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Woodward Diversified Capital LLC boosted its stake in Pfizer by 2.1% in the fourth quarter. Woodward Diversified Capital LLC now owns 30,172 shares of the biopharmaceutical company's stock valued at $751,000 after acquiring an additional 623 shares during the last quarter. Baugh & Associates LLC lifted its position in shares of Pfizer by 19.6% during the 4th quarter. Baugh & Associates LLC now owns 212,290 shares of the biopharmaceutical company's stock valued at $4,881,000 after buying an additional 34,733 shares during the last quarter. LVW Advisors LLC grew its stake in shares of Pfizer by 54.1% during the 4th quarter. LVW Advisors LLC now owns 17,937 shares of the biopharmaceutical company's stock worth $447,000 after acquiring an additional 6,299 shares during the period. Acropolis Investment Management LLC grew its stake in shares of Pfizer by 6.5% during the 4th quarter. Acropolis Investment Management LLC now owns 18,358 shares of the biopharmaceutical company's stock worth $457,000 after acquiring an additional 1,119 shares during the period. Finally, Legal Advantage Investments Inc. purchased a new stake in Pfizer in the 4th quarter worth about $361,000. Institutional investors own 68.36% of the company's stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Bank of America dropped their price objective on shares of Pfizer from $29.00 to $28.00 and set a "neutral" rating on the stock in a report on Monday, December 15th. UBS Group initiated coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a "neutral" rating and a $25.00 target price for the company. Daiwa Securities Group cut shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price target on the stock. in a research note on Thursday, February 12th. Argus raised shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price objective for the company in a report on Monday, March 2nd. Finally, BMO Capital Markets reiterated an "outperform" rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Pfizer has an average rating of "Hold" and a consensus price target of $28.19.

Pfizer Stock Down 2.0%

PFE stock opened at $27.03 on Friday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The firm has a market capitalization of $153.70 billion, a PE ratio of 19.88 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The stock has a 50-day simple moving average of $26.84 and a two-hundred day simple moving average of $25.69.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer's revenue was down 1.2% compared to the same quarter last year. During the same period last year, the business earned $0.63 earnings per share. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.